Principal Scientist - Immunogenicity and Ligand Binding Assays
About the job
- A Ph.D. in infectious disease, immuno-oncology, immunology, cancer biology, or a related field and a minimum of 10+ years of industry biotechnology or pharmaceutical experience; a Master of Science with extensive bioanalytical experience is also considered.
- Ability to effectively communicate scientific concepts, program objectives, and data analysis within a matrix environment.
- Knowledge of Good Laboratory Practice requirements and current industry trends and regulatory expectations associated with bioanalytical science.
- Provide scientific and hands-on oversight of ligand binding assay-based bioanalyses supporting mRNA-lipid nanoparticle therapeutic development programs.
- Support and oversee the immunogenicity function through clinical science-driven, phase-appropriate, and risk-based bioanalytical development strategies across advancing stages of clinical development.
- Lead and facilitate anti-drug antibody assay and neutralizing antibody assay regulated method development, validation, and clinical sample testing activities.
- Ensure in-house Good Clinical Laboratory Practice compliance across the ligand binding assay team, systems, and procedures.
- Design and execute phase-appropriate clinical analytical strategies supporting development programs.
- Drive development, validation, and implementation of cell-based assays, immunoassays, quantitation of translated proteins, pharmacokinetic assays, and pharmacodynamic assays.
- Review and evaluate raw analytical data, assay validation data, and study reports to ensure scientific integrity, data quality, and compliance with applicable standards.
- Assess analytical performance and laboratory compliance to ensure generated data meet scientific and regulatory expectations.
- Collaborate with internal and external stakeholders to support clinical bioanalytical activities throughout the product development lifecycle.
- Contribute to regulatory submissions and support responses to regulatory authority questions and information requests.
- Maintain current knowledge of scientific literature, industry best practices, regulatory expectations, and evolving guidance related to clinical bioanalysis.
- Ensure adherence to Good Clinical Laboratory Practice, Good Laboratory Practice, Good Clinical Practice, internal standard operating procedures, applicable regulations, guidance documents, and relevant white papers.
- Apply scientific judgment and risk-based decision-making to support robust bioanalytical strategies while maintaining quality and compliance.
- Partner with multidisciplinary teams to advance analytical approaches and improve laboratory and bioanalytical processes.
- Experience with RNA, biologics, and cell therapy.
- Experience with platforms such as electrochemiluminescence, Gyrolab, reporter gene assays, DELFIA assays, and other methodologies for clinical assays.
- Experience with Watson laboratory information management system and LabVantage electronic laboratory notebooks.
About the company
Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Get referred to Moderna
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
- April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
- Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.
What critics are saying
- September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
- July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
- If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.
What makes Moderna unique
- Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
- September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
- Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
401(k) Company Match
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Merck chief executive officer Rob Davis expects the company's personalised cancer vaccine with Moderna to become faster to make over time. He told CNBC the current timeline is six weeks, from sequencing a patient's tumour to delivering the shot to the hospital. "I do think over time you're going to see that timeline shortened," Davis said. For now, the focus is on readying supply and the market. The vaccine targets the mutations in each patient's tumour and is paired with Merck's immunotherapy Keytruda. In August, the companies released positive initial late-stage data in melanoma patients. Trials are also under way in lung, bladder, and kidney cancers. Davis spoke as Merck opened its 120,000-square-foot research facility, Advance, in West Point, Pennsylvania.
Moderna shares jumped 14.2% on October 9 to close at $225, after reports of an NIH-backed cancer vaccine initiative. The rally also coincided with the company's addition to the Nasdaq-100 index. Novavax rose 15.8%. The Foundation for the NIH describes the Therapeutic Cancer Vaccines Initiative as a $200 million public-private effort to coordinate trials, research infrastructure, and shared data. The funding is not revenue awarded to Moderna, and no direct financial benefit has been confirmed. Moderna's revenue fell from $6.85 billion in fiscal 2023 to $1.94 billion in fiscal 2025. Analysts expect $3.39 billion by fiscal 2028. Before the rally, the stock traded at about 41.3 times next-twelve-month sales, against a five-year average of 7.3 times. On October 24, Moderna and Merck will present Phase 3 melanoma therapy data at the ESMO Congress.
Moderna (NASDAQ:MRNA) shares up 8.3% - Here's why. Moderna, Inc. (NASDAQ:MRNA - Get Free Report) was up 8.3% during trading on Friday. The company traded as high as $207.74 and last traded at $213.3890. 2,813,170 shares traded hands during trading, a decline of 77% from the average session volume of 12,095,529 shares. The stock had previously closed at $197.00. More Moderna news. Here are the key news stories impacting Moderna this week: * Nasdaq-100 reentry may drive additional demand. Moderna is scheduled to rejoin the Nasdaq-100 before the October 9 market open, replacing Warner Bros. Discovery. The inclusion follows a substantial rise in Moderna's market capitalization and could prompt buying by index-tracking funds, providing a near-term technical tailwind. * Investors are increasingly focused on Moderna's cancer opportunity. Moderna and Merck are expanding development of the individualized neoantigen therapy intismeran autogene, also known as V940 or mRNA-4157, including studies in melanoma and other cancers. The collaboration with Tempus is intended to support potential commercialization and strengthens the long-term oncology narrative. * Manufacturing capabilities are becoming a key part of the bull case. Recent coverage highlights Moderna's efforts to apply lessons from its COVID-era production network to manufacture future cancer therapies at commercial scale. Successful execution could improve confidence in the company's ability to convert its pipeline into revenue. * Analyst sentiment remains cautious. Morgan Stanley reportedly assigned Moderna a "Hold" rating, suggesting that the recent rally may already reflect substantial optimism about the oncology pipeline and index inclusion. * Execution and valuation risks are rising after the surge. Commentary emphasizes that scaling cancer manufacturing will be a major test, while reports that insiders are trimming holdings could add to concerns that the stock has moved ahead of near-term fundamentals. Analyst ratings changes. A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Moderna from $40.00 to $77.00 and gave the stock an "underweight" rating in a research report on Friday, August 21st. CLSA upgraded shares of Moderna to an "outperform" rating in a research report on Friday, August 28th. Brookline Capital Markets restated a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Argus raised shares of Moderna from a "hold" rating to a "buy" rating and set a $180.00 target price for the company in a report on Friday, August 28th. Finally, Rothschild & Co Redburn lowered Moderna from a "neutral" rating to a "sell" rating and increased their price target for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $78.17. Moderna stock performance. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The business has a 50 day moving average price of $136.67 and a 200 day moving average price of $83.94. The stock has a market cap of $84.14 billion, a P/E ratio of -26.37 and a beta of 1.09. Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period last year, the company earned ($2.13) earnings per share. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, sell-side analysts expect that Moderna, Inc. will post -6.09 EPS for the current year. Insiders place their bets. In other Moderna news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company's stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares of the company's stock, valued at $219,921,913.54. The trade was a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,882 shares of company stock worth $16,862,280 in the last ninety days. 10.80% of the stock is owned by company insiders. Institutional inflows and outflows. Institutional investors and hedge funds have recently modified their holdings of the company. TD Waterhouse Canada Inc. lifted its holdings in Moderna by 2.6% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company's stock valued at $246,000 after purchasing an additional 85 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 8.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 1,976 shares of the company's stock valued at $381,000 after purchasing an additional 159 shares during the period. Assetmark Inc. lifted its stake in Moderna by 35.1% during the 1st quarter. Assetmark Inc. now owns 801 shares of the company's stock worth $41,000 after acquiring an additional 208 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Moderna by 13.8% during the third quarter. Versant Capital Management Inc now owns 2,491 shares of the company's stock worth $480,000 after purchasing an additional 302 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Moderna by 21.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company's stock valued at $63,000 after buying an additional 387 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock. About Moderna. Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company's work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases. Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
Tempus enters multiyear collaboration with Moderna, Merck aimed at commercializing cancer drug. Published on 10/07/2026 at 09:26 am EDT - Modified on 10/07/2026 at 09:27 am EDT By Kelly Cloonan Tempus is doubling down on its work with Moderna and Merck under a new multiyear collaboration to support the potential commercialization of a cancer drug. The healthcare-technology company said Wednesday the collaboration will focus on intismeran autogene, a therapy being evaluated in combination with Merck's Keytruda in patients with completely resected stage IIB-IV melanoma and other cancer types. Moderna and Merck are jointly developing intismeran autogene. As part of the collaboration, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing, the company said. The collaboration expands work that Tempus initiated with Moderna and Merck last year. Moderna said working with Tempus will allow it to use the company's commercial footprint and advanced sequencing capabilities to help it provide individualized neoantigen therapies at scale. "Bringing an individualized therapy like intismeran autogene from clinical development toward potential commercialization requires a seamless, highly reliable diagnostic network," said Said Francis, Moderna's chief business officer and general manager, individualized neoantigen therapies. Write to Kelly Cloonan at [email protected] (END) Dow Jones Newswires 10-07-26 0925ET (C) Dow Jones - 2026
Tempus announces multi-year collaboration with Moderna and Merck. Key Takeaway: Tempus has announced a multi-year collaboration with Moderna and Merck to support the commercialization of intismeran autogene, a novel individualized neoantigen therapy. This therapy is being evaluated in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma and other cancers. The collaboration signifies a significant step in cancer treatment innovation. Market sentiment analysis. Positive factors. * Collaboration aims to support commercialization of innovative therapy. * Intismeran autogene is a potential first-in-class treatment. * Combination therapy with KEYTRUDA may enhance cancer treatment options. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 9 past catalysts Cash runway Minimal dilution risk Lead asset Phase 2 · Influenza CHICAGO-(BUSINESS WIRE)-Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA(R)(pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know Frequently asked questions. What is the focus of the Tempus collaboration? The collaboration focuses on supporting the commercialization of intismeran autogene. Which therapy is intismeran autogene combined with? Intismeran autogene is evaluated in combination with KEYTRUDA. What types of cancer are targeted in this collaboration? The collaboration targets completely resected stage IIB-IV melanoma and other cancers. Who are the partners in the collaboration? The partners are Tempus, Moderna, and Merck.